Jazz Pharmaceuticals Public
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals Public's revenues will increase 122.0% and EPS will grow 56.7%.
The average estimate for revenue is $185.4 million. On the bottom line, the average EPS estimate is $1.41.
Last quarter, Jazz Pharmaceuticals Public reported revenue of $175.5 million. GAAP reported sales were much higher than the prior-year quarter's $73.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.34. GAAP EPS of $0.55 for Q3 were 20% lower than the prior-year quarter's $0.69 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 87.3%, 740 basis points worse than the prior-year quarter. Operating margin was 39.7%, 1,440 basis points worse than the prior-year quarter. Net margin was 18.9%, 2,540 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $592.4 million. The average EPS estimate is $4.59.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 213 members out of 279 rating the stock outperform, and 66 members rating it underperform. Among 75 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Jazz Pharmaceuticals Public a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $64.33.
- Add Jazz Pharmaceuticals Public to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.